Table 1.
Baseline characteristics
| Empagliflozin, n=43 | Placebo, n=44 | |
|---|---|---|
| Age, yr (SD) | 74 (14) | 76 (12) |
| Sex, women (%) | 27 (63) | 28 (64) |
| BMI, kg/m2 (SD) | 24.0 (4.1) | 23.1 (4.9) |
| Systolic BP, mm Hg (SD) | 138 (17) | 142 (21) |
| Diastolic BP, mm Hg (SD) | 69 (15) | 75 (14) |
| Heart rate, (bpm) | 73 (10) | 75 (16) |
| Comorbidities, n (%) | ||
| Cardiovascular disease | 31 (72) | 33 (75) |
| Cerebrovascular disease | 6 (14) | 10 (23) |
| Pulmonary disease | 6 (14) | 9 (21) |
| Diabetes mellitus type 2 | 6 (14) | 6 (14) |
| Psychiatric disease | 9 (21) | 11 (25) |
| Causes of SIAD, n (%) | ||
| Central nervous system disorders | 5 (12) | 10 (23) |
| Nausea/pain | 6 (14) | 9 (21) |
| Trauma/postoperative | 3 (7) | 6 (14) |
| Drug induced (primarily antipsychotic/antiepileptic drugs) | 9 (21) | 5 (11) |
| Pulmonal disease | 4 (9) | 6 (14) |
| Infectious diseases | 4 (9) | 3 (7) |
| Malignant disease | 7 (16) | 1 (2) |
| Idiopathic | 5 (12) | 4 (9) |
Summary statistics of patient characteristics according to the full analysis set. Categorical variables are shown as frequencies (percentage), and numerical variables are shown as mean (SD). BMI, body mass index.